Onboarding of siponimod in secondary progressive multiple sclerosis patients in Australia: Novel, real-world evidence from the MSGo digital support programme.
Todd A HardyP AouadMichael Harry BarnettStefan BlumSimon A BroadleyW M CarrollD CrimminsD GriffithsS HodgkinsonJ Lechner-ScottA LeeR MalhotraP McCombeJ ParrattC PlummerAnneke Van Der WaltK MartelR A WalkerPublished in: Multiple sclerosis journal - experimental, translational and clinical (2024)
Despite the limitations of self-reported data and the challenges of the COVID-19 pandemic, this study provides insights into siponimod onboarding in Australia and demonstrates the positive impact of care partner support.